Thursday, June 20, 2013

COMING THROUGH MEDSCAPE!
*35% of paroxysmal nocturnal hemoglobinuria (PNH) patients die within 5 years of diagnosis1 Three experts discuss how the pathophysiology of PNH can manifest in life-threatening complications such as chronic kidney disease, pulmonary hypertension, and thrombosis.

*GO TOARTICLE

Association of metformin use with cancer incidence and mortality: A meta-analysis
Cancer Epidemiology, 04/16/2013  Review Article

Zhang P et al. – Metformin can reduce the incidence of overall cancer, liver cancer, pancreatic cancer, colorectal cancer and breast cancer as well as the mortality of overall cancer, liver cancer and breast cancer. No beneficial effect on prostate cancer incidence was found for meformin intake in the meta-analysis."

*GO TO ARTICLE!

FDA Investigates 2 Deaths Involving Olanzapine

Mark Crane
Jun 18, 2013 The US Food and Drug Administration (FDA) is investigating 2 unexplained deaths of patients who received an intramuscular injection of the antipsychotic drug olanzapine pamoate (Zyprexa Relprevv, Eli Lilly).

No comments: